Katakura Industries (3001) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
23 Oct, 2026Executive summary
H1 net sales rose 0.4% YoY to ¥20,834 million; operating income increased 18.7% to ¥3,747 million, exceeding forecast.
Profit attributable to owners of parent rose 51.8% to ¥5,371 million, boosted by a ¥2,971 million gain on the sale of Hulic shares.
Full-year operating and ordinary income guidance was raised in August following H1 results.
Financial highlights
H1 net sales were ¥20,834 million, up ¥79 million YoY and ¥34 million above forecast; gross profit rose to ¥7,976 million from ¥7,525 million.
Operating income was ¥3,747 million, up ¥591 million YoY and ¥1,047 million above forecast; ordinary income was ¥4,523 million, up ¥653 million YoY.
Profit attributable to owners of parent was ¥5,371 million, up ¥1,833 million YoY and ¥771 million above forecast; EPS was ¥169.68 versus ¥110.26.
Operating margin rose to 18.0% from 15.2%; comprehensive income increased 64.1% to ¥4,052 million.
Extraordinary income included a ¥2,971 million gain on the sale of Hulic shares; prior-year extraordinary income of ¥1,250 million included gains from asset sales.
Outlook and guidance
FY2026 forecast: sales ¥41,100 million; operating income ¥5,800 million and 14.1% margin; ordinary income ¥7,200 million; profit attributable to owners of parent ¥7,450 million; EPS ¥235.27.
August revisions raised operating, ordinary and net income forecasts; the net income forecast had previously been raised in May due to the Hulic share-sale gain.
Machinery expects full-year sales and earnings in line with forecast, with deliveries adjusted for H1 delays and rising costs.
Latest events from Katakura Industries
- Profit growth outpaced revenue in Q1 FY2026, with real estate and pharma driving gains.3001
Q1 2026 - Revenue and profit fell on machinery and textile weakness, but real estate grew; dividend raised.3001
Q3 2024 - Q1 revenue and profit rose sharply, driven by machinery, with stable outlook and share buyback planned.3001
Q1 2025 - Net income surged 90.4% year-over-year, driven by machinery gains and asset sales.3001
Q3 2025 - Strong profit growth driven by machinery and real estate; cautious FY2026 outlook.3001
Q4 2025 - Revenue fell 4.7% YoY, with stable operating profit and ongoing pharma restructuring.3001
Q2 2024 - Operating and net income rose despite lower sales, with higher dividends and FY2025 growth forecast.3001
Q4 2024 - Net income nearly doubled on strong machinery sales and asset gains; full-year outlook raised.3001
Q2 2025